Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.01), $0.20 better than the analyst estimate of ($1.21).

We made significant achievements from both a regulatory and clinical perspective this quarter and look to build on this momentum as we continue through the regulatory process for eteplirsen, our lead product candidate,” said Edward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer. “We believe the recently published FDA draft guidance for Duchenne muscular dystrophy illustrates that the FDA is being responsive to the needs of patients and is open to providing appropriate flexibility in cases of unmet medical need and serious and life threatening diseases, such as Duchenne muscular dystrophy.”

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.